BioDelivery Sciences International, Inc. (NASDAQ:BDSI) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other equities research analysts also recently issued reports on BDSI. FBR & Co set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, February 2nd. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, February 8th. Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, March 6th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $3.00 price target on shares of BioDelivery Sciences International in a report on Monday, March 20th. Finally, Cantor Fitzgerald set a $3.00 price target on BioDelivery Sciences International and gave the company a “hold” rating in a report on Wednesday, March 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.67.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 6.52% during midday trading on Friday, reaching $2.45. 2,116,056 shares of the company’s stock were exchanged. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.10. The company’s 50 day moving average is $1.80 and its 200-day moving average is $1.88. The stock’s market cap is $135.55 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.49. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The business had revenue of $29.48 million during the quarter, compared to the consensus estimate of $27.07 million. Equities analysts forecast that BioDelivery Sciences International will post $0.06 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “BioDelivery Sciences International, Inc. (BDSI) Upgraded to “Hold” at ValuEngine” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/19/biodelivery-sciences-international-inc-bdsi-upgraded-to-hold-at-valuengine.html.

In other news, CEO Mark A. Sirgo sold 110,895 shares of BioDelivery Sciences International stock in a transaction on Friday, March 31st. The stock was sold at an average price of $1.90, for a total transaction of $210,700.50. Following the completion of the sale, the chief executive officer now owns 1,670,157 shares of the company’s stock, valued at $3,173,298.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 112,345 shares of company stock valued at $213,456 in the last three months. Insiders own 9.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Broadfin Capital LLC increased its stake in BioDelivery Sciences International by 4.0% in the fourth quarter. Broadfin Capital LLC now owns 5,398,794 shares of the specialty pharmaceutical company’s stock worth $9,448,000 after buying an additional 210,000 shares in the last quarter. Stonepine Capital Management LLC increased its stake in BioDelivery Sciences International by 9.4% in the first quarter. Stonepine Capital Management LLC now owns 2,844,820 shares of the specialty pharmaceutical company’s stock worth $5,405,000 after buying an additional 244,109 shares in the last quarter. Vanguard Group Inc. increased its stake in BioDelivery Sciences International by 2.0% in the first quarter. Vanguard Group Inc. now owns 2,271,519 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 44,036 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its stake in BioDelivery Sciences International by 5.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after buying an additional 56,550 shares in the last quarter. Finally, Blair William & Co. IL increased its stake in BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock worth $1,386,000 after buying an additional 189,484 shares in the last quarter. 53.57% of the stock is owned by institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.